Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
NCT04382066
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
Plitidepsin 1.5 mg/day
DRUG:
Plitidepsin 2.0 mg/day
DRUG:
Plitidepsin 2.5 mg/day
Sponsor
PharmaMar
Collaborators
[object Object]